CDMO — Avid Bioservices Income Statement
0.000.00%
Last trade - 00:00
- $466.58m
- $585.55m
- $149.27m
- 50
- 41
- 52
- 45
2019 April 30th | 2020 April 30th | 2021 April 30th | 2022 April 30th | 2023 April 30th | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 53.6 | 59.7 | 95.9 | 120 | 149 |
Cost of Revenue | |||||
Gross Profit | 7.22 | 3.93 | 29.3 | 36.6 | 31.5 |
Selling / General / Administrative Expenses | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 59.2 | 70.6 | 83.6 | 104 | 146 |
Operating Profit | -5.62 | -10.9 | 12.2 | 15.4 | 3.6 |
Total Net Non Operating Interest Income / Expense | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -5.34 | -10.5 | 11.2 | 12.7 | 2 |
Provision for Income Taxes | |||||
Net Income After Taxes | -5.06 | -10.5 | 11.2 | 128 | 0.56 |
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | -4.21 | -10.5 | 11.2 | 128 | 0.56 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -8.9 | -15.2 | 3.32 | 128 | 0.56 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.174 | -0.263 | 0.056 | 1.81 | 0.009 |